Novartis says top R&D executives no longer at Avexis unit after test data manipulation

Novartis said on Wednesday the two top research & development executives at its Avexis unit were no longer at the company after some data from early testing of Avexis’s more than $2-million gene therapy Zolgensma was manipulated.

Source: Reuters Health

Be the first to comment

Leave a Reply

Your email address will not be published.